Masin D - Search Results

1

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.

Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT. Verreault M, et al. Among authors: masin d. BMC Cancer. 2011 Apr 8;11:124. doi: 10.1186/1471-2407-11-124. BMC Cancer. 2011. PMID: 21477311 Free PMC article.

2

Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267.

Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strut D, Osooly M, Masin D, Bally MB. Kalra J, et al. Among authors: masin d. Cancer Biol Ther. 2011 May 1;11(9):826-38. doi: 10.4161/cbt.11.9.15183. Epub 2011 May 1. Cancer Biol Ther. 2011. PMID: 21358264 Free PMC article.

3

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB. Dragowska WH, et al. Among authors: masin d. BMC Cancer. 2011 Oct 1;11:420. doi: 10.1186/1471-2407-11-420. BMC Cancer. 2011. PMID: 21961653 Free PMC article.

4

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.

Waterhouse DN, Sutherland BW, Santos ND, Masin D, Osooly M, Strutt D, Ostlund C, Anantha M, Harasym N, Manisali I, Wehbe M, Bally MB, Webb MS. Waterhouse DN, et al. Among authors: masin d. Invest New Drugs. 2014 Dec;32(6):1071-82. doi: 10.1007/s10637-014-0138-x. Epub 2014 Jul 27. Invest New Drugs. 2014. PMID: 25064374 Free PMC article.

5

Development of glioblastoma cell lines expressing red fluorescence for non-invasive live imaging of intracranial tumors.

Verreault M, Strutt D, Masin D, Fink D, Gill R, Bally MB. Verreault M, et al. Among authors: masin d. Anticancer Res. 2011 Jun;31(6):2161-71. Anticancer Res. 2011. PMID: 21737636

6

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB. Verreault M, et al. Among authors: masin d. J Control Release. 2012 Feb 28;158(1):34-43. doi: 10.1016/j.jconrel.2011.09.095. Epub 2011 Oct 5. J Control Release. 2012. PMID: 22001870

7

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.

Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB. Verreault M, et al. Among authors: masin d. J Control Release. 2015 Dec 28;220(Pt A):348-357. doi: 10.1016/j.jconrel.2015.10.053. Epub 2015 Nov 1. J Control Release. 2015. PMID: 26528901

8

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

Waterhouse DN, Gelmon KA, Masin D, Bally MB. Waterhouse DN, et al. Among authors: masin d. J Exp Ther Oncol. 2003 Sep-Oct;3(5):261-71. doi: 10.1111/j.1533-869x.2003.01099.x. J Exp Ther Oncol. 2003. PMID: 14696623

9

In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.

Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. Abraham SA, et al. Among authors: masin d. Clin Cancer Res. 2004 Jan 15;10(2):728-38. doi: 10.1158/1078-0432.ccr-1131-03. Clin Cancer Res. 2004. PMID: 14760096

10

Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.

Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Warburton C, et al. Among authors: masin d. Clin Cancer Res. 2004 Apr 1;10(7):2512-24. doi: 10.1158/1078-0432.ccr-03-0244. Clin Cancer Res. 2004. PMID: 15073131

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters